This is a randomised phase III open-label trial to examine the effect of intravenous iron replacement on anaemia and anaemia-related symptoms in breast cancer patients receiving adjuvant chemotherapy. It is hoped that this research will improve the quality of life of women undergoing adjuvant chemotherapy for breast cancer.
Who is it for?
This study may be suitable if you are 18 years or older and will be starting adjuvant chemotherapy to treat early or locally advanced resected breast cancer.
Study details
Participants will be randomly allocated to receive either:
All participants will be regularly monitored every 5-6 weeks (depending on the type of chemotherapy) throughout treatment to evaluate their health. There will be a final treatment visit one cycle-length after the last dose of chemotherapy. Follow-up visits will occur at six weeks, three months, six months and 12 months after the last dose of chemotherapy. Further treatment will be at the discretion of the participant and their treating clinician.
At each visit, all participants will:
This trial is due to open in Q3/4 2021.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Subscribe for updates & stay in the loop with new studies.